MAYZENT is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.1
The summary of product characteristics (SmPC) of MAYZENT can be found in the Downloadable resources section or can be viewed on the emc website by clicking here.
MAYZENT is now the first and only oral treatment recommended by NICE and SMC for adults living with SPMS with active disease
Siponimod is recommended, within its marketing authorisation, as an option for treating secondary progressive multiple sclerosis with evidence of active disease (that is, relapses or imaging features of inflammatory activity) in adults.
This advice applies only in the context of an approved NHS Scotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/list price that is equivalent or lower.
- MAYZENT (siponimod) Summary of Product Characteristics.
- https://www.nice.org.uk/guidance/ta656/resources/siponimod-for-treating-secondary-progressive-multiple-sclerosis-pdf-82609202014405 [Accessed November 2020].
- https://www.scottishmedicines.org.uk/media/5468/siponimod-mayzent-final-september-2020-for-website.pdf [Accessed November 2020].